Maybe Fuller wanted this but T said no, the numbers still won't...

Maybe Fuller wanted this but T said no, the numbers still won't be there, we need to focus on Europe where the numbers are. Reading between Fuller's (minimal) lines, it could well be he was frustrated, but if it was over Australia vs Europe then the latter would have to be the path forward.
There's MC's quasi-insider comment on FB about a replacement being not a bad thing, and T's about RAC not being a typical biotech in terms of CSO/CMO division of labour.
Between the runes and the eyebrow-twitches, this seems to me like a positive development, albeit one that implies some delay. Hopefully management can get on with managing without feeling stressed over artificial deadlines such as 'marketing to BP by the end of the year' (they are already doing this).Things happen as they happen.